Revolution Medicines reaffirms FY2022 net loss guidance of $245M–$265M

Revolution Medicines, Inc.

2022-FY EPS reported -$3.08 revenue$35,380,000

Net loss expected to be between $245M and $265M for the year ended December 31, 2022.
Includes estimated non-cash stock-based compensation of approximately $30M to $35M.
Company also posted a corporate presentation on January 10, 2023, covering its R&D pipeline.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported the year ended December 31, 2022 results: net income between $245 million and $265 million. Guidance reaffirmed.

Period: the year ended December 31, 2022
Net income: between $245 million and $265 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

On January 10, 2023, Revolution Medicines, Inc. (the “Company”) confirmed to investors that it continues to expect that its net loss for the year ended December 31, 2022 to be between $245 million and $265 million, which includes estimated non-cash stock-based compensation expense of approximately $30 million to $35 million.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.